These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 31772320)

  • 1. Therapeutic host-directed strategies to improve outcome in tuberculosis.
    Young C; Walzl G; Du Plessis N
    Mucosal Immunol; 2020 Mar; 13(2):190-204. PubMed ID: 31772320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review.
    Kiran D; Podell BK; Chambers M; Basaraba RJ
    Semin Immunopathol; 2016 Mar; 38(2):167-83. PubMed ID: 26510950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospects in Mycobacterium bovis Bacille Calmette et Guérin (BCG) vaccine diversity and delivery: why does BCG fail to protect against tuberculosis?
    Moliva JI; Turner J; Torrelles JB
    Vaccine; 2015 Sep; 33(39):5035-41. PubMed ID: 26319069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Recent progress in mycobacteriology].
    Okada M; Kobayashi K
    Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding the Reciprocal Interplay Between Antibiotics and Host Immune System: How Can We Improve the Anti-Mycobacterial Activity of Current Drugs to Better Control Tuberculosis?
    Park HE; Lee W; Shin MK; Shin SJ
    Front Immunol; 2021; 12():703060. PubMed ID: 34262571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New tricks for old dogs: countering antibiotic resistance in tuberculosis with host-directed therapeutics.
    Hawn TR; Shah JA; Kalman D
    Immunol Rev; 2015 Mar; 264(1):344-62. PubMed ID: 25703571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural and trained innate immunity against Mycobacterium tuberculosis.
    Ferluga J; Yasmin H; Al-Ahdal MN; Bhakta S; Kishore U
    Immunobiology; 2020 May; 225(3):151951. PubMed ID: 32423788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of autophagy as a strategy for development of new vaccine candidates against tuberculosis.
    Flores-Valdez MA; Segura-Cerda CA; Gaona-Bernal J
    Mol Immunol; 2018 May; 97():16-19. PubMed ID: 29547747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of epigenetics, bacterial and host factors in progression of Mycobacterium tuberculosis infection.
    Marimani M; Ahmad A; Duse A
    Tuberculosis (Edinb); 2018 Dec; 113():200-214. PubMed ID: 30514504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autophagy Induction as a Host-Directed Therapeutic Strategy against
    Adikesavalu H; Gopalaswamy R; Kumar A; Ranganathan UD; Shanmugam S
    Medicina (Kaunas); 2021 May; 57(6):. PubMed ID: 34070995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repurposing Tamoxifen as Potential Host-Directed Therapeutic for Tuberculosis.
    Boland R; Heemskerk MT; Forn-Cuní G; Korbee CJ; Walburg KV; Esselink JJ; Carvalho Dos Santos C; de Waal AM; van der Hoeven DCM; van der Sar E; de Ries AS; Xie J; Spaink HP; van der Vaart M; Haks MC; Meijer AH; Ottenhoff THM
    mBio; 2023 Feb; 14(1):e0302422. PubMed ID: 36475748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repurposing Immunomodulatory Drugs to Combat Tuberculosis.
    Fatima S; Bhaskar A; Dwivedi VP
    Front Immunol; 2021; 12():645485. PubMed ID: 33927718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibiotic Treatment Shapes the Antigenic Environment During Chronic TB Infection, Offering Novel Targets for Therapeutic Vaccination.
    Chuang YM; Dutta NK; Gordy JT; Campodónico VL; Pinn ML; Markham RB; Hung CF; Karakousis PC
    Front Immunol; 2020; 11():680. PubMed ID: 32411131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Host-Directed Therapeutics as a Novel Approach for Tuberculosis Treatment.
    Kim YR; Yang CS
    J Microbiol Biotechnol; 2017 Sep; 27(9):1549-1558. PubMed ID: 28683527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Host-directed therapy against mycobacterium tuberculosis infections with diabetes mellitus.
    Zhao L; Fan K; Sun X; Li W; Qin F; Shi L; Gao F; Zheng C
    Front Immunol; 2023; 14():1305325. PubMed ID: 38259491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid rebound of the Treg compartment in DEREG mice limits the impact of Treg depletion on mycobacterial burden, but prevents autoimmunity.
    Berod L; Stüve P; Varela F; Behrends J; Swallow M; Kruse F; Krull F; Ghorbani P; Mayer CT; Hölscher C; Sparwasser T
    PLoS One; 2014; 9(7):e102804. PubMed ID: 25050936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is interferon-gamma the right marker for bacille Calmette-Guérin-induced immune protection? The missing link in our understanding of tuberculosis immunology.
    Abebe F
    Clin Exp Immunol; 2012 Sep; 169(3):213-9. PubMed ID: 22861360
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 23.